Full-Time

Bioinformatics Scientist

Computational Biology

Volastra Therapeutics

Volastra Therapeutics

11-50 employees

Clinical-stage biopharma developing CIN-targeting cancer drugs

Compensation Overview

$140k - $180k/yr

New York, NY, USA

In Person

PhD

Category
Biology & Biotech (1)
Required Skills
LLM
Bash
Python
R
Git
Docker
Linux/Unix

Get referred to Volastra Therapeutics

See people who can refer or advise you

Requirements
  • PhD or equivalent experience in bioinformatics, computational biology, genomics, computational oncology, systems biology, bioengineering, computer science, or a related quantitative life-science field.
  • Deep hands-on experience analyzing high-throughput sequencing data, especially transcriptomic and cancer genomic data.
  • Strong coding ability in Python and/or R, with Unix/Linux and bash proficiency.
  • Familiarity with cloud or HPC environments and scalable handling of large biological datasets.
  • Biological insight in oncology, cancer genomics, chromosomal instability, DNA damage response, synthetic lethality, targeted therapy, or drug resistance.
  • Ability to communicate complex analyses to biologists, chemists, translational scientists, clinicians, and leadership with clarity and judgment.
  • High scientific integrity, intellectual ownership, and comfort working in a fast-moving, hypothesis-driven team.
  • Experience in target discovery, biomarker discovery, patient population mapping, translational genomics, or computational oncology.
  • Experience analyzing functional genomics screens, Perturb-seq, CRISPR dependencies, cell line or organoid datasets, pharmacogenomic response data, or multi-omics perturbation studies.
  • Experience building reusable internal tools, structured analysis reports, or lightweight dashboards for project teams.
  • Familiarity with clinical genomics assay outputs and exploratory biomarker workflows.
  • Track record of collaborating with wet-lab scientists to turn computational hypotheses into experiments and decisions.
  • Experience using AI coding assistants, code agents, or LLM-based developer tools in a way that improves quality, speed, testing, and documentation.
Responsibilities
  • Lead bioinformatics analyses across discovery sciences and translational sciences, including RNA-seq, single-cell RNA-seq, whole-exome sequencing, whole-genome sequencing, copy number, mutation, structural variant, CRISPR screen, proteomic, or other omics datasets as appropriate.
  • Develop reproducible, well-documented computational workflows for quality control, processing, feature engineering, integrated analysis, visualization, and reporting.
  • Integrate internal experimental datasets with public cancer resources such as TCGA, DepMap, CCLE, CPTAC, cBioPortal, and relevant disease-specific cohorts to prioritize targets and biomarkers.
  • Build analyses that connect cancer genotype, lineage, CIN biology, dependency, perturbation response, and therapeutic hypotheses.
  • Partner with discovery teams to design experiments, interpret results, refine hypotheses, and identify the next best biological test.
  • Support translational strategy by connecting preclinical models, patient genomics, and biomarker hypotheses. Work with clinical colleagues when analyses intersect with clinical samples, patient selection concepts, or exploratory biomarker readouts.
  • Translate complex data into clear recommendations for project teams and leadership, with concise visualizations and transparent assumptions.
  • Build durable code: modular Python and/or R packages, workflow management, data provenance, testing, version control, documentation, containers, and cloud or HPC execution.
  • Use AI coding assistants and LLM-based tools to accelerate code generation, refactoring, unit-test drafting, documentation, pipeline scaffolding, and exploratory analysis. Treat AI output as draft code that must be reviewed, tested, documented, and validated.
  • Help define technical standards for reproducible bioinformatics across the organization and mentor colleagues as appropriate.
Volastra Therapeutics

Volastra Therapeutics

View

Volastra Therapeutics develops cancer therapies focused on chromosomal instability (CIN), a feature present in many tumors and linked to aggressive disease. Its core strategy is discovering and developing drugs that inhibit KIF18A, a protein essential for cancer-cell division, with two lead programs in Phase I/II for KIF18A inhibitors such as VLS-1488. The company advances drug candidates through clinical trials and aims to bring them to patients with aggressive cancers, building its pipeline through ongoing preclinical work and data sharing from conferences like AACR. Compared with competitors, Volastra combines a CIN-targeted approach with KIF18A inhibition to address tumors characterized by chromosomal instability, seeking to translate preclinical findings into clinically tested therapies. The goal is to provide effective treatments for patients with CIN-associated cancers and to progress multiple candidates through development toward commercialization."

Company Size

11-50

Company Stage

Early VC

Total Funding

$119M

Headquarters

New York City, New York

Founded

2019

Get referred to Volastra Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • AACR 2026 data linked p16-positive tumors to responses across 15% of cancers.
  • FDA Fast Track for sovilnesib in platinum-resistant HGSOC accelerates regulatory interactions.
  • March 2026 lab relocation to Alexandria Center signals operational expansion and hiring readiness.

What critics are saying

  • VLS-1488 Phase I/II completion in June 2026 leaves a near-term binary readout.
  • Single-mechanism KIF18A dependence concentrates failure risk if p16-selected tumors underperform.
  • Cash pressure stays opaque; no 2026 financing disclosure supports an existential runway risk.

What makes Volastra Therapeutics unique

  • Volastra owns first-in-class KIF18A inhibitors, sovilnesib and VLS-1488, targeting CIN biology.
  • AACR 2026 p16 loss data created a pan-cancer, Rb pathway-driven biomarker strategy.
  • Microsoft, Function Oncology, and Tailor Bio partnerships strengthen biomarker-guided patient selection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-2%

2 year growth

0%
Yahoo Finance
Apr 17th, 2026
Volastra identifies p16 loss as biomarker for KIF18A inhibitor response across 15% of cancers

Volastra Therapeutics has announced data identifying p16 loss as a candidate predictive biomarker for KIF18A inhibition, establishing a pan-cancer development strategy for its therapies. The findings were disclosed around the American Association for Cancer Research Annual Meeting 2026. The clinical-stage oncology company released a study analysing 79 heavily pretreated high-grade serous ovarian cancer patients treated with KIF18A inhibitors sovilnesib and VLS-1488. Biomarker-positive tumours showed significant enrichment for objective responses, durable disease control and longer progression-free survival. The research identifies Rb pathway inactivation as the mechanistic basis of response to KIF18A inhibition, potentially applicable to approximately 15% of human cancers. Volastra's proprietary p16 IHC biomarker strategy aims to translate this biology into clinical patient selection across multiple tumour types.

Volastra Therapeutics
May 27th, 2025
Volastra Therapeutics Announces Appointment of David P. Southwell as Chief Executive Officer

NEW YORK - may 27, 2025 - Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the appointment of David P. Southwell as Chief Executive Officer.

Business Wire
May 22nd, 2025
Volastra Announces Initial Data from First-in-Human Phase I/II Trial of Novel KIF18A Inhibitor VLS-1488 to be Presented at 2025 ASCO Annual Meeting

Volastra announces initial data from first-in-human Phase I/II trial of novel KIF18A inhibitor VLS-1488 to be presented at 2025 ASCO Annual Meeting.

Fierce Biotech
Oct 16th, 2024
Chromosomal instability biotech Volastra taps CSO as it looks to 'expand the operation'

As it transitions from a discovery- to a clinical-stage biotech, Volastra Therapeutics is bringing longtime adviser Samuel Bakhoum, M.D., Ph.D., on board as its chief scientific officer.

U.S. Securities and Exchange Commission
Jun 1st, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.